Hormone therapy used to target ER and PR is suitable for ER- and PR-positive breast cancer patients [2]; however, patients with TNBC have fewer treatment options than patients with other types of breast cancer due to the absence of therapeutic targets such as ER, PER, and HER2 [3]. This evidence concerns the gene ERBB2 and breast carcinoma.